Evidence map›Paper›PMID 29790124›Full record

ReviewDrugs2018

Colorectal Cancer: Why Does Side Matter?

Claire Gallois, Simon Pernot, Aziz Zaanan, Julien Taieb

Abstract readReview
PubMed Publisher
In one paragraph

Review in Drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 4 pooled it
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. [What is confirmed in the treatment of colon cancer?]Innere Medizin (Heidelberg, Germany) · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Claire GalloisDepartment of Gastroenterology and Digestive Oncology, Assistance Publique-Hôpitaux De Paris, Hôpital Européen Georges Pompidou, Paris Descartes University, Paris, France.
Simon PernotDepartment of Gastroenterology and Digestive Oncology, Assistance Publique-Hôpitaux De Paris, Hôpital Européen Georges Pompidou, Paris Descartes University, Paris, France.
Aziz ZaananDepartment of Gastroenterology and Digestive Oncology, Assistance Publique-Hôpitaux De Paris, Hôpital Européen Georges Pompidou, Paris Descartes University, Paris, France.
Julien TaiebDepartment of Gastroenterology and Digestive Oncology, Assistance Publique-Hôpitaux De Paris, Hôpital Européen Georges Pompidou, Paris Descartes University, Paris, France. jtaieb75@gmail.com.
Hôpital Européen Georges-Pompidou · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is a heterogeneous disease, and the search for clinical and molecular prognostic and predictive factors is thus necessary to better tailor each individual patient's management. Primary tumor location (PTL) seems to act as a master prognostic factor pooling different clinical, pathological, and molecular poor prognostic factors. In fact, right-sided (RS) CRC patients are more frequently female and elderly with microsatellite unstable, BRAF mutated, CpG island methylator phenotype (CIMP)-high, poorly differentiated tumors, compared to left-sided (LS) CRC patients. PTL does not seem to clearly influence disease-free survival (DFS) in localised colon cancer even though the opposite prognostic value of RS tumors on DFS depending on RAS/BRAF mutational status has been recently suggested in these patients. In metastatic CRC (mCRC), the poor prognosis associated with RS tumors is confirmed in the most recent publications in the era of double and triple chemotherapeutic regimens and targeted agents. Concerning the predictive value of PTL, in patients with RAS wild-type mCRC in the first-line setting, anti-epidermal growth factor receptor (EGFR) therapy combined with chemotherapy appears to be more effective than bevacizumab in LS CRC, while patients with RS CRC benefit less from anti-EGFR therapy, and intensive chemotherapy plus bevacizumab may be more appropriate but EGFR antibodies remain an option if objective response is needed. Due to the limitation of the current data (unplanned and retrospective analyses), these conclusions must be interpreted with caution. Clinical trials in RS CRC may be of interest to clarify what is the best treatment strategy in these patients.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBevacizumabColorectal NeoplasmsDisease-Free SurvivalErbB ReceptorsHumansMolecular Targeted TherapyMutationNeoplasm MetastasisPrognosisBevacizumabErbB Receptors

Identifiers

PMID29790124
OpenAlexW2804640180

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.